Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
Simple item page
Full item details
- dc.contributor.author
- Cao, Huibi
- Mai, Juntao
- Zhou, Zhichang
- Li, Zhijie
- Duan, Rongqi
- Watt, Jacqueline
- Chen, Ziyan
- Bandara, Ranmal Avinash
- Li, Ming
- Ahn, Sang Kyun
- Poon, Betty
- Christie-Holmes, Natasha
- Gray-Owen, Scott D.
- Banerjee, Arinjay
- Mossman, Karen
- Kozak, Rob
- Mubareka, Samira
- Rini, James M.
- Hu, Jim
- Liu, Jun
- dc.date.accessioned
- 2025-01-24T20:19:24Z
- dc.date.available
- 2025-01-24T20:19:24Z
- dc.date.issued
- 2021-12-08
- dc.description.abstract - en
- <p>Background<br> The ongoing COVID-19 pandemic has resulted in 185 million recorded cases and over 4 million deaths worldwide. Several COVID-19 vaccines have been approved for emergency use in humans and are being used in many countries. However, all the approved vaccines are administered by intramuscular injection and this may not prevent upper airway infection or viral transmission.</p> <p>Results<br> Here, we describe a novel, intranasally delivered COVID-19 vaccine based on a helper-dependent adenoviral (HD-Ad) vector. The vaccine (HD-Ad_RBD) produces a soluble secreted form of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and we show it induced robust mucosal and systemic immunity. Moreover, intranasal immunization of K18-hACE2 mice with HD-Ad_RBD using a prime-boost regimen, resulted in complete protection of the upper respiratory tract against SARS-CoV-2 infection.</p> <p>Conclusion<br> Our approaches provide a powerful platform for constructing highly effective vaccines targeting SARS-CoV-2 and its emerging variants.</p>
- dc.description.sponsorship
- This work was supported by Canadian Institutes of Health Research (CIHR) Grants VR1-172771 and VS-1-17553138 (to JL, JH and JMR). Indirect support was also received from the University of Toronto and the Temerty Foundation to support enhanced capacity and operations of the Toronto Combined Containment Level 3 Facility during the COVID-19 pandemic.
- dc.identifier.doi
- https://doi.org/10.1186/s13578-021-00723-0
- dc.identifier.issn
- 2045-3701
- dc.identifier.pubmedID
- 34879865
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3353
- dc.language.iso
- en
- dc.publisher - en
- BioMed Central Ltd.
- dc.rights - en
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights - fr
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights.openaccesslevel - en
- Gold
- dc.rights.openaccesslevel - fr
- Or
- dc.rights.uri - en
- https://creativecommons.org/licenses/by/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.subject.en - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.title - en
- Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
- dc.type - en
- Article
- dc.type - fr
- Article
- local.acceptedmanuscript.articlenum
- 202
- local.article.journaltitle - en
- Cell & Bioscience
- local.article.journalvolume
- 11
- local.pagination
- 1-13
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: cao-intranasal-hd-ad-vaccine-respiratory-tracts-mice-sars-cov-2.pdf
Size: 5.53 MB
Format: PDF
Collection(s)